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Introduction: Irisin is a newly identified cytokine that has gained increasing attention
because of its potential therapeutic applications in metabolic diseases and human cancers.
Recently, accumulating evidence indicates that irisin plays an important role in the devel-
opment and metastasis of various tumors. The aim of this study was to evaluate the effects
and underlying mechanisms of irisin on malignant growth of pancreatic cancer cells.
Materials and methods: The anti-proliferative effect of irisin was examined using the
CCK-8 assay. Irisin-induced apoptosis was determined by the annexin V-FITC/PI staining
assay. The effects of irisin on cell migration and invasion were assessed using the scratch-
induced wound healing assay and transwell invasion assay, respectively. The expression and
phosphorylation of signaling proteins were detected by Western blot analysis.
Results: Our results showed that irisin inhibited cell proliferation and induced apoptosis of
pancreatic cancer cells in a dose-dependent manner. In addition, irisin decreased the migra-
tion and invasion of pancreatic cancer cells. Finally, Western blot analysis revealed that irisin
downregulated the PI3K/AKT signaling pathway.
Conclusion: Our findings suggest that irisin is a novel therapeutic agent for pancreatic cancer.
Keywords: irisin, pancreatic cancer, cell growth, migration, apoptosis
Introduction
Pancreatic cancer is one of the most malignant digestive tract tumors. The prog-
nosis of pancreatic cancer is extremely poor due to its rapid progression, late-stage
diagnosis, and early metastasis. Although surgical resection is the only choice for
the current therapy, only 20% of patients are capable of radical excision.1,2 The
5-year survival rate among patients with pancreatic cancer is <7%, which is the
lowest one among all cancer types.3,4 Therefore, it is of utmost importance to
develop novel and effective therapeutic strategies, which may help to improve
overall outcomes of pancreatic cancer patients.
Irisin, a recently identified myokine by Bostrom et al (2013), is secreted from
fibronectin type III domain containing 5 (FNDC5) expressing cells during exercise.5,6
In addition to skeletal muscle, irisin is widely expressed in brain, heart, stomach,
pancreas, liver, testis, and adipose, suggesting that irisin is involved in many biolo-
gical functions.7–9 Irisin dissipates the energy in the form of heat by inducing the
white fat tissue into the brown adipose tissue that contains a large number of
uncoupling protein-1 (UCP-1) in mitochondria.5,10 Therefore, several studies have
shown that irisin regulates glucose homeostasis, improves insulin resistance, and
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ameliorates cognitive function.11–13 Recently, irisin has
been implicated in the development and metastasis of
tumors, including breast and colorectal cancers, and pro-
posed as a novel diagnostic marker and even therapeutic
target.14,15 In this study, however, we unexpectedly found
irisin to exhibit anticancer activities in the pancreatic cancer
cells and explored its underlying mechanism.
Materials and methods
Cell lines and culture conditions
Human pancreatic cancer cell lines, PANC-1 and BxPC-3,
were obtained from the Cell Bank of Chinese Academy of
Sciences (Shanghai, China) and routinely maintained in
DMEM medium (Hyclone, UT, USA) supplemented with
10% fetal bovine serum, 100 U/mL penicillin and
100 µg/mL streptomycin (Hyclone, UT, USA) in 25 cm2
culture flasks. The cells were maintained at 37 °C in a
humidified atmosphere of 5% CO2. PANC-1 and BxPC-3
are epithelioid carcinoma cell lines, isolated from pancrea-
tic carcinoma of ductal cell origin.
Cell counting kit-8 (CCK-8) assay
The cells were grown in 96-well plates at a density of
5×103 cells/well overnight. Following day, cells were trea-
ted with 0 nM, 10 nM, 20 nM, and 50 nM of irisin
(Cayman Chemicals, MI, USA) for different periods
(24 h, 48 h, and 72 h) at 37 °C. The effect of irisin on
cell proliferation was assayed using the CCK-8 (7Sea
Biotech, Shanghai, China) according to the manufacturer’s
instructions. The CCK-8 solution was added and incubated
for 1 h at 37 °C and the absorbance was measured using a
microplate reader (Bio-Tek, VT, USA) at 450 nm.
The annexin-V-FITC/PI assay
The cells were seeded at a density of 2×105 cells/well in
6-well plates and treated with different concentrations of
irisin for 24 h. Next, cells were collected, washed twice
with PBS, gently re-suspended and incubated with the
binding buffer of the annexin V-FITC/PI staining kit
(7Sea Biotech, Shanghai, China). Cells were subsequently
stained with 5 μl annexin V-FITC and 10 μl PI in the dark
for 15 min and analyzed by using an Accuri C6 Flow
Cytometer (BD Biosciences, CA, USA).
Scratch-induced wound healing assay
Cells were seeded in 6-well plates containing regular growth
medium and allowed to grow till confluence. A single scratch
wound was generated in the confluent monolayer cells using
a pipette tip and was rinsed with PBS. The scratched cells
were then cultured in DMEM treated with or without 50 nM
irisin and incubated for 24 h. Images were acquired at 0 h
and 24 h at the same position (scratched area) using an
inverted microscope (Olympus, Tokyo, Japan). The percen-
tage of wound closure was calculated by measuring the
healed area relative to the initial wound area.
Transwell invasion assay
The invasion potential of the pancreatic cancer cells trea-
ted with irisin was assessed using transwell invasion
chambers (8-μm pore size; Corning Incorporated, NY,
USA) coated with 30 µl of Matrigel (BD Biosciences,
NJ, USA). The cell suspensions (5 x 104) were added to
the upper chamber containing serum-free DMEM medium.
The lower chamber was filled with 600 μL DMEM sup-
plemented with 10% fetal bovine serum. After 24 h of
incubation at 37 °C, the non-invaded cells in the upper
surface of the filter were removed with cotton swabs. The
cells that had invaded the underside of the membrane were
fixed with 4% paraformaldehyde at room temperature for
20 min and stained with 0.1% crystal violet. The stained
cells from at least 3 random fields were counted under a
microscope at high magnification.
Western blot analysis
The cells cultured in 6-well plates were lysed with the
RIPA buffer. The concentration of total protein was mea-
sured using the BCA protein assay kit (Beyotime,
Shanghai, China). Proteins of equal amounts from differ-
ent cell lysates were separated on an SDS-PAGE and then
transferred to PVDF membrane (Beyotime, Shanghai,
China). The membranes were blocked in 5% fat-free
milk at room temperature and incubated with primary
antibodies overnight at 4 °C. Primary antibodies against
AKT, p-AKT, Bax, Bcl-2, and β-actin were purchased
from Cell Signaling Technology, Inc. (MA, USA). The
membranes were then washed with TBST and incubated
with HRP-conjugated secondary antibodies for 2 h at room
temperature. The immune complexes were detected using
the ECL method (Millipore, MA, USA).
Statistical analysis
Experiments were carried out in triplicates and presented
as mean ± standard deviation (SD). Statistical analysis was
performed using GraphPad Prism 7 software (GraphPad
Software Inc., CA, USA). The experimental data was
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tested for normality. The comparison between two groups
was analyzed by Student’s t-test. Comparisons among
multiple groups were analyzed with one-way analysis of
variance (ANOVA) followed by Dunnett’s test. P<0.05
was considered statistically significant.
Results
Irisin decreased the proliferation of
pancreatic cancer PANC-1 and BxPC-3
cells
We used the CCK-8 assay to examine the effects of different
concentrations of irisin on the proliferation of PANC-1 and
BxPC-3 cells. Our results showed that irisin was able to
reduce proliferation of both PANC-1 and BxPC-3 cells in a
dose-dependent manner (Figure 1). Thus, BxPC-3 cells
were used for subsequent experiments in this study.
Irisin induced apoptosis of the pancreatic
cancer BxPC-3 cells
To investigate the mechanism by which irisin inhibited cell
proliferation, we performed the annexin V-FITC/PI double
staining assay to test whether irisin induces apoptosis of
these cells treated with different concentrations of irisin
for 24 h. We found that irisin significantly increased the
apoptosis of treated cells in a dose-dependent manner
(Figure 2A). To further examine the underlying mechan-
ism of apoptosis induced by irisin, the levels of mitochon-
drial apoptotic pathway proteins such as Bax and Bcl-2
were evaluated by Western blot analysis. The results
showed that the level of pro-apoptotic protein Bax was
increased while anti-apoptotic protein Bcl-2 decreased
following treatment with irisin (Figure 2B).
Irisin attenuated migration and invasion of
pancreatic cancer BxPC-3 cells
The effects of irisin on BxPC-3 cell migration was exam-
ined by the scratch-induced wound-healing assay. The
result showed that irisin significantly inhibited wound
closure in BxPC3 cells compared with that in the control
cells (Figure 3A).
Transwell assay was performed to investigate the effect
of irisin on the invasion ability of BxPC-3 cells. After
treatment with irisin, the number of cells that invaded
through the Matrigel-coated membrane was significantly
reduced compared with the control group. These results
indicate that irisin has potential in inhibiting the invasive
ability of BxPC-3 cells (Figure 3B).
Irisin downregulated the activity of the
PI3K/AKT signaling pathway
The PI3K/AKT signaling pathway is important in the
development and progression of pancreatic cancer.
Further, our data revealed that irisin downregulated the
levels of the p-AKT in a dose-dependent manner without
affecting the levels of total AKT protein (Figure 4).
Discussion
In recent years, accumulating evidence indicates that irisin
is involved in the occurrence and development of a variety
of tumors. The positive immunoreactivity of irisin in can-
cer tissues, such as pancreatic, gastric, and breast cancers
is significantly increased compared with that in normal
tissues.16,17 However, serum levels of irisin in breast and
colorectal cancer patients were significantly reduced com-
pared with healthy controls, suggesting that serum irisin
Figure 1 Irisin inhibited the growth of pancreatic cancer cells.
Notes: PANC-1 and BxPC-3 cells were treated with irisin (0 nM, 10 nM, 20 nM, and 50 nM) for indicated periods (24 h, 48 h, and 72 h) and then subjected to the CCK-8
assay. *P<0.05, **P<0.01, and ***P<0.001 compared with control.
Dovepress Zhang et al

































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
may serve as a novel diagnostic biomarker of cancer.14,15
Irisin has been reported to possess an antitumor effect in
different tumors such as breast, lung, and prostate cancers
as well as osteosarcoma.18–21 In this study, we investigated
the anti-tumor activity of irisin in pancreatic cancer cells
and explored the potential mechanisms. We found that
irisin can inhibit the growth of pancreatic cancer cells in
a dose-dependent manner.
In addition, we employed the annexin V-FITC/PI staining
assay to evaluate the effect of irisin on the apoptosis of BxPC-
3 cells. The results showed that irisin increased the apoptotic
cell proportions in a dose-dependent manner. Induction of
apoptosis in tumor cells is an important cellular process to
eliminate malignant cells while preventing tumor develop-
ment. Bcl-2 protein family members play an essential role in
mitochondria-mediated apoptosis pathway via regulating the
anti-apoptotic protein Bcl-2 and the pro-apoptotic protein Bax.
Here, we found that irisin elevated the levels of Bax protein
and reduced Bcl-2 protein levels in BxPC-3 cells, suggesting
that irisin induces the apoptosis of BxPC-3 cells presumably
via the mitochondrial apoptosis pathway. Invasion and metas-
tasis are the major biological cellular activities of malignant
tumors, which often are the main cause of the most deaths in
cancer patients. Therefore, it is crucial to find new therapeutic
agents to prevent cell invasion andmetastasis for the treatment
and prevention of cancer recurrence, which might be useful in
prolonging the survival of the patients. In our study, at 24 h
after irisin treatment, the migration and the invasive abilities of
BxPC-3 cells were remarkably reduced.
The PI3K/AKT signaling pathway is involved in sev-
eral cellular processes, including cell proliferation, differ-
entiation, survival, and motility.22 It has been reported that
the expression and activity of the PI3K and AKT are
upregulated in pancreatic cancer cells, which is associated
with poor prognosis.23,24 It is well known that the PI3K/
AKT signaling pathway is a key regulatory pathway not
only in pancreatic tumorigenesis but also in the treatment
of other cancers.25 It has been reported that irisin reduces
the migration and invasion of lung cancer cells via inhibit-
ing the PI3K/AKT signaling pathway.20 Irisin has also
Figure 2 Irisin induced apoptosis in pancreatic cancer cells. BxPC-3 cells were treated with irisin (0 nM, 10 nM, 20 nM and 50 nM) for 24 h. (A) Apoptosis was analyzed
using the annexin V-FITC/PI double staining assay. (B) The effect of irisin on the levels of Bax and Bcl-2 was determined by Western blotting. *p<0.05, **p<0.01, and
***p<0.001 compared with control.
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been demonstrated to increase the number and function of
endothelial progenitor cells via the PI3K/AKT pathway.26
In the present study, we observed that irisin inhibited the
levels of the p-AKT protein, suggesting that irisin attenu-
ated the activity of the PI3K/AKT signaling pathway in
BxPC-3 cells. While preparing this manuscript, a related
work was published, which showed the potential of irisin
in suppressing pancreatic cancer cell growth via the
AMPK-mTOR signaling pathway.27 However, they did
not evaluate the effect of irisin on apoptosis of pancreatic
cancer cells and its mechanism of action. Induction of
tumor cell apoptosis is an important cellular activity
through which anti-tumor drugs exert their therapeutic
effects. Here, we further illustrate the effect of irisin on
the induction of apoptosis in pancreatic cancer cells, which
was associated with alteration of levels between Bax and
Bcl-2 proteins. In addition, irisin attenuated the activity of
the PI3K/AKT signaling pathway, which was also
Figure 3 Irisin inhibited migration and invasion of pancreatic cancer cells.
Notes: (A) After treatment with indicated concentrations of irisin, the scratch-induced wound healing assay was used to measure cell migration at 24 h after scratch
wounding confluent cell layer. (B) Transwell assay was used to determine the effect of irisin on the invasion of pancreatic cancer cells. Images of cells were captured using an
inverted microscope following staining with crystal violet. *P<0.05 and **P<0.01 compared with control cells.
Figure 4 Irisin suppressed the protein phosphorylation of the PI3K/AKT signaling pathway.
Notes: BxPC-3 cells were treated with irisin (0 nM, 10 nM, 20 nM, and 50 nM) for 24 h. The levels of total AKT, p-AKT, and Actin were analyzed by Western blot. *P< 0.05
and ***P<0.001 compared with control.
Dovepress Zhang et al
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involved in cancer cell apoptosis via interactions with the
Bcl-2 family.
Conclusion
In conclusion, our findings suggest that irisin could inhibit
cell proliferation and induce the apoptosis of pancreatic
cancer cells. In addition, irisin was able to downregulate
the activation of the PI3K/AKT signaling pathway in pan-
creatic cancer cells. These findings provide strong evi-
dence to suggest that irisin may be further developed as
a novel potential therapeutic agent for the treatment of
pancreatic cancer. Further studies are needed to understand
the precise role of irisin in pancreatic cancer in vivo.
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